Kawasaki disease, formerly known as the mucocutaneous lymph node syndrome, is a less commonly observed childhood disease that affects the blood vessels in children. This disease is a form of the condition known as vasculitis, which involves inflammation of the blood vessels. Kawasaki disease could lead to cardiovascular complications where it affects the coronary arteries carrying oxygenated blood to the heart. However, the frequency of cardiovascular complications has drastically reduced with the use of intravenous immune globulin (IVIG) therapy. The causes of Kawasaki disease are not well understood; however, it is assumed that the body’s response to different pathogenic microorganisms and viruses combined with genetic factors lead to the development of Kawasaki disease symptoms. Common symptoms of Kawasaki disease include fever which lasts for more than five days, red eyes & lips, and redness on the palms and feet soles. Various guidelines have been developed by the regulatory authorities for the treatment of the disease. Infusion of gamma globulins through intravenous route and dosage of aspirin are the most common therapeutic medications used to relieve the symptoms.

Kawasaki disease is becoming one of the most frequent causes of pediatric acquired heart disease in most of the developed countries such as the U.S., the U.K., Japan, Germany, and France. Prevalence of the disease is high in developing countries such as Brazil, China, India, and Russia. Moreover, this disease mostly affects boys than girls, and occurs in children aged between two years and five years. Rapid rise in incidence of Kawasaki disease in the emerging countries is likely to drive demand for therapeutic drugs during the forecast period. Increase in adoption of intravenous immunoglobulin therapy to prevent or reduce the coronary artery problems is projected to drive the Kawasaki disease therapeutics market during the forecast period. Furthermore, the underlining clinical trials using different drugs such as steroids and infliximab to treat the disease as the second line and tertiary treatment present significant opportunity in the near future.

The global Kawasaki disease therapeutics market can be segmented based on route of administration, distribution channel, and region. In terms of route of administration, the global market can be categorized into oral and intravenous. The intravenous segment is likely to dominate the global Kawasaki disease therapeutics market during the forecast period. The intravenous segment is projected to record high growth rate owing to increased adoption of this therapy for the prevention of cardiovascular complications. Based on distribution channel, the global Kawasaki disease therapeutics market can be segmented into hospital pharmacy, retail pharmacy, and e-commerce. The hospital pharmacy segment is anticipated to hold significant share by 2025. The retail pharmacy segment is projected to expand at the fastest growth rate during the forecast period.

Geographically, the global Kawasaki disease therapeutics market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are projected to account for high share of the global Kawasaki disease therapeutics market by 2025. According to the Kawasaki Disease Foundation, in the U.S. over 4,200 children are diagnosed with the disease each year. The market in Asia Pacific is projected witness exponential growth during the forecast period owing to increase in incidence of acquired heart disease caused due to Kawasaki disease. Japan is likely to dominate the market in the region during the forecast period.

Key players operating in the global Kawasaki disease therapeutics market include Shire plc, CSL Behring LLC, Grifols S.A., LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, Sanquin Plasma Products B.V., Bayer AG, and Novartis AG.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Kawasaki Disease Therapeutics Market

Pre Book